Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200
Debt
Debt-to-Equity Ratio0.01
Current Ratio5.59
Quick Ratio4.15
Price-To-Earnings
Trailing P/E Ratio26.28
Forward P/E Ratio28.07
P/E Growth1.41
Sales & Book Value
Annual Sales$560.87 million
Price / Sales5.88
Cash Flow$2.7985 per share
Price / Cash23.57
Book Value$18.47 per share
Price / Book3.57
Profitability
EPS (Most Recent Fiscal Year)$1.90
Net Income$82.59 million
Net Margins16.55%
Return on Equity15.09%
Return on Assets11.91%
Miscellaneous
Employees1,256
Outstanding Shares50,020,000
Market Cap$3.30 billion
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent Biosolutions' stock buyback program work?
Emergent Biosolutions declared that its board has approved a stock repurchase plan on Friday, March 23rd 2018, which permits the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) posted its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.88 by $0.19. The biopharmaceutical company had revenue of $220.20 million for the quarter, compared to the consensus estimate of $208.94 million. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. Emergent Biosolutions's revenue for the quarter was up 118.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.13 earnings per share. View Emergent Biosolutions' Earnings History.
When is Emergent Biosolutions' next earnings date?
What price target have analysts set for EBS?
7 brokerages have issued 12-month price targets for Emergent Biosolutions' stock. Their forecasts range from $49.00 to $70.00. On average, they expect Emergent Biosolutions' stock price to reach $61.8571 in the next twelve months. This suggests that the stock has a possible downside of 6.2%. View Analyst Price Targets for Emergent Biosolutions.
What is the consensus analysts' recommendation for Emergent Biosolutions?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Emergent Biosolutions.
What are Wall Street analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
- 1. According to Zacks Investment Research, "Emergent beat both revenue and earnings estimates in Q2. The company recorded high sales for both anthraxvaccine BioThrax as well as smallpox vaccine ACAM2000. The increase in BioThrax sales was primarily owing to the favorable timing of BioThrax deliveries to the SNS. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the company’s cost structure. Shares have outperformed the broader industry so far this year. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturg BioThrax. This in turn, also raises a concern." (8/20/2018)
- 2. Cantor Fitzgerald analysts commented, ". Post 2Q18, we are reiterating our Overweight rating and 12- month price target of $62. Emergent has successfully established itself as a leader in the biodefense field and has carved out a high-barrier-to-entry niche in that market. We believe the company’s business is a lot more durable than the Street is giving the company credit for. We expect Emergent to extend a number of its current contracts beyond current estimates. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on its products. The company has set a goal of $1B in revenue, which we expect it to reach through the renewal of contracts, pipeline advancements and business development." (8/2/2018)
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC), Valeant Pharmaceuticals (VRX), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS) and Alkermes (ALKS).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)
- Mr. Daniel J. Abdun-Nabi, CEO & Director (Age 63)
- Mr. Robert G. Kramer Sr., Pres & COO (Age 61)
- Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 47)
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.74%), Renaissance Technologies LLC (4.13%), Dimensional Fund Advisors LP (4.07%), Acadian Asset Management LLC (3.05%), Standard Life Aberdeen plc (2.87%) and Northern Trust Corp (2.30%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which major investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd., Acadian Asset Management LLC, Dimensional Fund Advisors LP, LSV Asset Management, Federated Investors Inc. PA, Standard Life Aberdeen plc and Convergence Investment Partners LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.
Which major investors are buying Emergent Biosolutions stock?
EBS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, FMR LLC, Rice Hall James & Associates LLC, Northern Trust Corp, Tributary Capital Management LLC, Meritage Portfolio Management and American Century Companies Inc.. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $65.96.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $3.30 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.
What is Emergent Biosolutions' official website?
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
